Who we are Cardio R&D Oncology R&D Careers News Contact News & Events News SalubrisBio parent company Salubris Pharmaceuticals announces IND approval of JK07 Phase I study in China September 21, 2020 SalubrisBio parent company Salubris Pharmaceuticals announces $265M investment from the Carlyle Group to further innovative R&D September 1, 2020 SalubrisBio announces IND approval by FDA of JK07 Phase I study in the US February 24, 2020 SalubrisBio parent company Salubris Pharmaceuticals announces partnership with JT Pharmaceuticals (Tokyo, Japan) to commercialize HIF-PH inhibitor enarodustat for the treatment of renal anemia in China: December 25, 2019 SalubrisBio parent company Salubris Pharmaceuticals announces investment of $10M in Viracta Therapeutics (San Diego, USA) to support development of their kick-and-kill combination cancer therapy December 4, 2018 SalubrisBio parent company Salubris Pharmaceuticals announces investment of $20M in MedAlliance SA (Nyon, Switzerland) to support development of their novel sirolimus-coated balloon for coronary and peripheral vascular diseases May 22, 2018 SalubrisBio parent company Salubris Pharmaceuticals announces investment of $8M in Mercator Medsystems (Emeryville, USA) to support development of their novel microinjection platform technology June 21, 2018 SalubrisBio parent company Salubris Pharmaceuticals announces investment of $5M in GO Therapeutics (Cambridge, USA) to support development of their novel microinjection platform technology June 21, 2018 Upcoming Events Please check back soon for future events Salubris Biotherapeutics, Inc © 2017-2020 | Privacy Policy | Terms & Conditions | site by Pierrot

Who we are Cardio R&D Oncology R&D Careers News Contact Focus Areas With our focus on complex biologics, we aim to widen the therapeutic window of cancer treatments, making them more effective and better tolerated. Our approaches include combining biologically active proteins, activating the immune system against cancer-specific targets, and delivering anti-cancer agents directly and specifically to tumors. Please return to our website in the future to check for updates on our cancer-targeted therapies in development Salubris Biotherapeutics, Inc © 2017-2020 | Privacy Policy | Terms & Conditions | site by Pierrot